These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 24166495)

  • 1. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
    Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
    Cironi L; Petricevic T; Fernandes Vieira V; Provero P; Fusco C; Cornaz S; Fregni G; Letovanec I; Aguet M; Stamenkovic I
    Sci Rep; 2016 Feb; 6():22113. PubMed ID: 26905812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Wnt pathway in synovial sarcoma models.
    Barham W; Frump AL; Sherrill TP; Garcia CB; Saito-Diaz K; VanSaun MN; Fingleton B; Gleaves L; Orton D; Capecchi MR; Blackwell TS; Lee E; Yull F; Eid JE
    Cancer Discov; 2013 Nov; 3(11):1286-301. PubMed ID: 23921231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
    de Bruijn DR; Allander SV; van Dijk AH; Willemse MP; Thijssen J; van Groningen JJ; Meltzer PS; van Kessel AG
    Cancer Res; 2006 Oct; 66(19):9474-82. PubMed ID: 17018603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex.
    Pretto D; Barco R; Rivera J; Neel N; Gustavson MD; Eid JE
    Oncogene; 2006 Jun; 25(26):3661-9. PubMed ID: 16462762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
    Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
    Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
    Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
    Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SS18-SSX drives CREB activation in synovial sarcoma.
    Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
    Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
    Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
    Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
    Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
    Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo.
    Takenaka S; Naka N; Araki N; Hashimoto N; Ueda T; Yoshioka K; Yoshikawa H; Itoh K
    Int J Oncol; 2010 Apr; 36(4):823-31. PubMed ID: 20198325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens.
    Kanemitsu S; Hisaoka M; Shimajiri S; Matsuyama A; Hashimoto H
    Diagn Mol Pathol; 2007 Mar; 16(1):9-17. PubMed ID: 17471153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
    Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
    PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.
    Nielsen TO; Poulin NM; Ladanyi M
    Cancer Discov; 2015 Feb; 5(2):124-34. PubMed ID: 25614489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
    Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
    Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wnt/β-catenin signaling mediates the antitumor activity of magnolol in colorectal cancer cells.
    Kang YJ; Park HJ; Chung HJ; Min HY; Park EJ; Lee MA; Shin Y; Lee SK
    Mol Pharmacol; 2012 Aug; 82(2):168-77. PubMed ID: 22550094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
    Zöllner SK; Rössig C; Toretsky JA
    Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.
    Peng C; Zhao H; Chen W; Song Y; Wang X; Li J; Qiao Y; Wu D; Ma S; Wang X; Gao C
    Oncotarget; 2016 Oct; 7(41):66822-66834. PubMed ID: 27572315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.